我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

经皮冠状动脉介入治疗患者造影剂肾病的发病率及其相关因素

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第2期
页码:
142-144
栏目:
临床研究
出版日期:
2014-10-25

文章信息/Info

Title:
Morbidity and related factors of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention
作者:
丁 琦欧阳茂
(中南大学湘雅三医院心内科,湖南 长沙 410013)
Author(s):
DING Qi OUYANG Mao
(Department of Cardiology, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China)
关键词:
造影剂肾病危险因素水化治疗经皮冠状动脉介入
Keywords:
contrast-induced nephropathy risk factor hydration percutaneous coronary intervention
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:调查分析他汀类药物和充分水化治疗后经皮冠状动脉介入(PCI)治疗患者的造影剂肾病(CIN)发病率和可能的危险因素。方法:连续入选PCI治疗的冠心病患者,分析PCI前后肾功能指标的变化,计算CIN的发病率,比较CIN组和非CIN组的相关指标,寻找可能的危险因素。结果:①本组患者CIN发病率为13.8%;②多因素相关性分析发现高龄、内生肌酐清除率、贫血、高血压是CIN的危险因素。结论:PCI患者正规治疗后CIN发病率与文献报道CIN平均发病率相比无明显降低,高龄、内生肌酐清除率、贫血、高血压病是CIN的独立危险因素。
Abstract:
AIM:To investigate the morbidity and risk factors of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI) after conventional treatment, including risk assessment before PCI, optimal hydration before and after PCI and statin therapy. METHODS: One hundred and eighty-one consecutive patients who underwent hydration and PCI were enrolled. Serum creatinine was measured before and 72 h after PCI. RESULTS: The morbidity of CIN was 13.8%. Multiple logistic regression analyses showed that CIN was associated with pre-contrast creatinine clearance, old age, lower hematocrit value and hypertension. CONCLUSION: The morbidity of CIN after conventional treatment is not noticeably lower than the average incidence reported in the literature. Pre-contrast creatinine clearance, old age, anemia and hypertension are independent risk factors for CIN.

参考文献/References

[1]Hou SH,Bushinsky DA,Wish JB, et al.Hospital-acquired renal insufficiency: A prospective study[J].Am J Med,1983,74(2):243-248.
[2]Mehran R,Aymong ED,Nikolsky E,et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation[J].J Am Coll Cardiol,2004,44(7):1393-1399.
[3]Okumura K,Sone T.Risk assessment and prevention of contrast-induced nephropathy in patients undergoing coronary angiography[J].Intern Med,2012,51(6):519-521.
[4]Cockcroft DW,Gault MH.Prediction of creatinine clearance from serum creatinine[J].Nephron,1976,16(1):31-41.
[5]Mehran R,Nikolsky E.Contrast-induced nephropathy:definition,epidemiology, and patients at risk[J].Kidney Int Suppl,2006,(100):S11-S15.
[6]Briguori C,Airoldi F,D'andrea D,et al.Renal insufficiency following contrast media administration trial(REMEDIAL):a randomized comparison of 3 preventive strategies[J].Circulation,2007,115(10):1211-1217.
[7]Zhang BC,Li WM,Xu YW.High-dose statin pretreatment for the prevention of contrast-induced nephropathy:a meta-analysis[J].Can J Cardiol,2011,27(6):851-858.
[8]Perrin T,Descombes E,Cook S.Contrast-induced nephropathy in invasive cardiology[J].Swiss Med Wkly,2012, 142:w13608.
[9]Haase M,Devarajan P,Haase-Fielitz A,et al.The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury:a multicenter pooled analysis of prospective studies[J].J Am Coll Cardiol,2011,57(17):1752-1761.
[10]冠心病介入诊疗对比剂应用专家共识组.冠心病介入诊疗对比剂应用专家共识[J].中国心血管病研究,2010,8(12):881-889.
[11]Morcos SK,Thomsen HS,Webb J.Contrast-media-induced nephrotoxicity: a consensus report[J].Eur Radiol,1999,9(8):1602-1613.
[12]Waybill MM,Waybill PN.Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention[J].J Vasc Interv Radiol,2001, 12(1):3-9.

备注/Memo

备注/Memo:
收稿日期:2014-04-20.
通讯作者:欧阳茂,副教授,主要从事冠心病的诊治研究 Email:doctorouyang@126.com.
作者简介:丁琦,硕士生 Email:dingqi.6648020@163.com
更新日期/Last Update: 2014-11-18